Conclusion The evidence supports a nuanced conclusion regarding GLP-1 agonists for obesity in non-diabetic patients: they represent a significant therapeutic advance with game-changing potential currently limited by practical implementation challenges
Often, the reported mechanisms underlying proteolysis in cis, i.e., autoproteolysis, involve attack of a nucleophile, i.e., either Ser, Thr or Cys side chains, on the N-terminally preceding peptide bond through an N-O(S) acyl shift resulting in formation of an instable ester, which is hydrolyzed ultimately resulting in cleavage of the peptide chain 71,72,73,74,103,104,105
Maintaining healthy blood pressure is crucial for overall well-being
Studies suggest it may support weight loss of around 1.5-2 kg (3-5 pounds) over 12-16 weeks
Mediators of endoplasmic reticulum stress-induced apoptosis
a method of increasing the efficacy of a GLP-1 agonist described herein results in a decrease in blood levels of AST of at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80% or at least about 90% compared to the blood levels of AST after treatment with the GLP-1 agonist in the absence of foralumab
